Navigation Links
Array BioPharma To Present At The Wells Fargo Securities Research And Economics 2013 Healthcare Conference

BOULDER, Colo., June 13, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference in Boston.  The public is welcome to participate in the conference through a webcast on the Array BioPharma website.(Logo: Fargo Securities Research and Economics 2013 Healthcare ConferencePresenter:Ron Squarer, Chief Executive OfficerDate:Wednesday, June 19, 2013Time:9:15 a.m. Eastern Time Location:InterContinental Hotel,  Boston, MAWebcast:www.arraybiopharma.comAbout Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.
Novartis expects to begin Phase 3 trials evaluating Array-invented MEK162 in NRAS-mutant melanoma and in BRAF-mutant melanoma in 2013.  In addition, Array will begin a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the license agreement with Novartis in 2013.  AstraZeneca began a pivotal trial with selumetinib (an Array-invented drug) in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer during the second half of 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to


Tricia HaugetoArray BioPharma

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Array BioPharma Announces Exercise Of Underwriters Option To Purchase An Additional $17.25 Million Of 3.00% Convertible Senior Notes
2. New Date And Time For Array BioPharma Presentation At The Jefferies 2013 Global Healthcare Conference
3. Array BioPharma Announces Proposed Public Offering of Convertible Debt
4. Two Array Invented MEK Inhibitors Showcased At ASCO
5. Array BioPharma To Present At The Jefferies 2013 Global Healthcare Conference
6. Oncothyreon and Array Announce Collaboration to Develop and Commercialize anti-HER2 Compound ARRY-380
7. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
8. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
9. Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
10. New Versa HD System Tops Elektas Comprehensive Array of Cancer Management Solutions at 2nd ESTRO Forum
11. Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
Post Your Comments:
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):